SK plasma to sell Janssen’s anti-cancer treatment Dacogen in Korea
![SK plasma CEO Kim Seung-ju, right, and Janssen Korea CEO Cherry Huang take a photo after signing an agreement. [SK PLASMA]](https://koreajoongangdaily.joins.com/data/photo/2023/02/13/31413cac-f014-40b2-8912-b9f1090f5f4e.jpg)
SK plasma CEO Kim Seung-ju, right, and Janssen Korea CEO Cherry Huang take a photo after signing an agreement. [SK PLASMA]
SK plasma signed an agreement with Janssen Korea for the treatment that is used to treat myelodysplastic syndromes such as acute myeloid leukemia.
Under the agreement, SK has the exclusive rights to market and sell the treatment in Korea while Janssen Korea will be in charge of manufacturing it.
The size of the deal has not been declared, but the period extends to Dec. 31, 2025.
"With the latest cooperation, we are able to strengthen our portfolio as a pharmaceutical company that focuses on rare and intractable diseases," said SK plasma CEO Kim Seung-ju.
![Dacogen [SK PLASMA]](https://koreajoongangdaily.joins.com/data/photo/2023/02/13/b51a0781-d196-49f8-8c5c-3c4ac19f8812.jpg)
Dacogen [SK PLASMA]
BY SARAH CHEA [chea.sarah@joongang.co.kr]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)